LockBit 3.0 Ransomware Attack on ABL Inc.: A Critical Breach in Biopharmaceutical Cybersecurity

Incident Date: Apr 18, 2024

Attack Overview
VICTIM
ABL inc.
INDUSTRY
Healthcare Services
LOCATION
USA
ATTACKER
Lockbit
FIRST REPORTED
April 18, 2024

LockBit 3.0 Ransomware Attack on ABL Inc.

Company Profile

ABL Inc., a subsidiary of the French bioindustrial group Institut Mérieux, is a prominent player in the biopharmaceutical sector, specializing as a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO). Based in Maryland, USA, ABL Inc. boasts a revenue of $95.6 million and employs 397 individuals. The company is instrumental in the GMP manufacturing of virus-based therapies and vaccines, and supports preclinical and clinical studies with its advanced immunology and molecular laboratory assays.

Details of the Cyberattack

The LockBit 3.0 ransomware group, known for its disruptive cyber activities, has targeted ABL Inc., leading to the exfiltration of approximately 5 terabytes of sensitive data. This data includes critical information ranging from CEO and senior management documents to laboratory data and customer information. The attack has compromised over 200 different devices, highlighting a significant breach in ABL's cybersecurity measures.

Industry Standing and Vulnerabilities

The attacked company's prominence in the healthcare and biopharmaceutical industry, combined with its extensive handling of sensitive data, makes it an attractive target for cybercriminals. The nature of its operations, involving substantial data on therapies and vaccines, adds layers of risk, particularly if cybersecurity measures are not robust enough to ward off sophisticated threats like those posed by LockBit 3.0.

Sources

See Halcyon in action

Interested in getting a demo?
Fill out the form to meet with a Halcyon Anti-Ransomware Expert!

1
2
3
Let's get started
Next
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.